Concurrently, wortmannin—a broad-spectrum inhibitor of PI3 K/Akt/mTOR—enhances the antiproliferative effects of mesenchymal stem cell–conditioned medium (MSC-CM) in BC cells. This evidence concerns the gene AKT1 and breast cancer.